Cytocare 516 (10 vials x 5 ml)

Alcohol consumption should be strictly avoided for 24 hours before and after the procedure. As a vasodilator, alcohol can exacerbate post-injection swelling and increase the risk of visible bruising at the multiple injection points required for mesotherapy.

Treatment is not recommended for nursing mothers. While the HA is biocompatible, the systemic absorption of the multivitamin complex during lactation has not been clinically studied. It is best to wait until breastfeeding has fully ceased.

The standard treatment protocol involves a series of 3 to 6 sessions spaced 2 to 3 weeks apart. For a full-face treatment, 2.5 ml to 5 ml (half to one full vial) is typically administered using micro-injections into the superficial or middle dermis. The dosage is adjusted based on skin quality, following similar precision as advanced injection techniques used for deeper tissue work.

Post-injection reactions are usually minimal and include transient redness, tiny bumps (papules), or minor localized bruising. These symptoms generally resolve within 24 to 48 hours. Patients should be advised to follow our comprehensive aftercare guide to ensure rapid healing of the micro-injection sites. Any persistent irritation must be evaluated against our vascular safety protocols.

Cytocare 516 utilizes a dual-action mechanism: the non-crosslinked hyaluronic acid provides an immediate surge of hydration, while the CT50 complex provides the essential nutrients required for dermal repair. This stimulates the production of collagen and elastin, restoring the "biological age" of the skin. Unlike the Restylane NASHA technology which provides firm projection, Cytocare focuses on biochemical skin quality improvement.

The formulation contains 16 mg of non-crosslinked Hyaluronic Acid and the CT50 rejuvenating complex, which includes 20 amino acids, 11 vitamins, 14 minerals, and 5 nucleic acids to support dermal health.

Mesotherapy treatments are contraindicated during pregnancy. There is no clinical safety data regarding the impact of high-concentration vitamin and peptide complexes on fetal development. We prioritize safety standards and defer all elective injectables until after delivery.